In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients

Show full item record



Permalink

http://hdl.handle.net/10138/319460

Citation

Al-Samadi , A , Poor , B , Tuomainen , K , Liu , V , Hyytiäinen , A , Suleymanova , I , Mesimäki , K , Wilkman , T , Mäkitie , A , Saavalainen , P & Salo , T 2019 , ' In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients ' , Experimental Cell Research , vol. 383 , no. 2 , 111508 . https://doi.org/10.1016/j.yexcr.2019.111508

Title: In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients
Author: Al-Samadi, Ahmed; Poor, Benedek; Tuomainen, Katja; Liu, Ville; Hyytiäinen, Aini; Suleymanova, Ilida; Mesimäki, Karri; Wilkman, Tommy; Mäkitie, Antti; Saavalainen, Paivi; Salo, Tuula
Contributor: University of Helsinki, Clinicum
University of Helsinki, TRIMM - Translational Immunology Research Program
University of Helsinki, Department of Oral and Maxillofacial Diseases
University of Helsinki, Director and Common Matters
University of Helsinki, Research Programs Unit
University of Helsinki, HUSLAB
University of Helsinki, HUS Head and Neck Center
University of Helsinki, HUS Head and Neck Center
University of Helsinki, HUS Head and Neck Center
University of Helsinki, Immunobiology Research Program
University of Helsinki, Department of Oral and Maxillofacial Diseases
Date: 2019-10-15
Language: eng
Number of pages: 7
Belongs to series: Experimental Cell Research
ISSN: 0014-4827
URI: http://hdl.handle.net/10138/319460
Abstract: Objectives: Immunotherapy and personalized medicine therapeutics are emerging as promising approaches in the management of head and neck squamous cell carcinoma (HNSCC). In spite of that, there is yet no assay that could predict individual response to immunotherapy. Methods: We manufactured an in vitro 3D microfluidic chip to test the efficacy of immunotherapy. The assay was first tested using a tongue cancer cell line (HSC-3) embedded in a human tumour-derived matrix "Myogel/fibrin" and immune cells from three healthy donors. Next, the chips were used with freshly isolated cancer cells, patients' serum and immune cells. Chips were loaded with different immune checkpoint inhibitors, PD-L1 antibody and IDO 1 inhibitor. Migration of immune cells towards cancer cells and the cancer cell proliferation rate were evaluated. Results: Immune cell migration towards HSC-3 cells was cancer cell density dependent. IDO 1 inhibitor induced immune cells to migrate towards cancer cells both in HSC-3 and in two HNSCC patient samples. Efficacy of PD-L1 antibody and IDO 1 inhibitor was patient dependent. Conclusion: We introduced the first humanized in vitro microfluidic chip assay to test immunotherapeutic drugs against HNSCC patient samples. This assay could be used to predict the efficacy of immunotherapeutic drugs for individual patients.
Subject: Head and neck cancer
In vitro
Microfuidic chip
Personalized medicine
PD-Ll
IDO1
Immunotherapy
SQUAMOUS-CELL CARCINOMA
RECURRENT
PEMBROLIZUMAB
DISEASE
3122 Cancers
3111 Biomedicine
1182 Biochemistry, cell and molecular biology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
In_vitro_humani ... d_neck_cancer_patients.pdf 1.549Mb PDF View/Open
1_s2.0_S0014482719303507_main.pdf 1.887Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record